Posts Archive

NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma NCT05427812: Phase 1/2 Study of ISB 1442 in...

NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma The...

BMT CTN 1902 NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902 MM CAR-T to Upgrade Response BMT CTN 1902 This study is...

Talquetamab Phase 1b study NCT05050097: phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple...

IGNITE STUDY - ALLO-605: IGNITE STUDY UTILIZING FIRST TurboCAR™ TO TARGET BCMA NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an...

NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple...

NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma Newly Diagnosed Multiple Myeloma...

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma The purpose of...

Talquetamab Phase 2 A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma A Study of Talquetamab in...

A Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma This is a Phase 1, multicenter, open label, study of...

UNIVERSAL Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma...

MajesTEC1 study A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1) Relapsed & Refractory...

CC-98633 CART NCT04394650: Phase 1 - A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With...

Official Title: A Phase 2 Study of Subcutaneous Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalidomide, and...

KarMMa-4 A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4) Relapsed...

Study CC-99712-MM-001 This is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical...

CARTITUDE-2 Ciltacabtagene Autoleuce A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell...

AURIGA Study A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly...

NCT03858205: Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma Low-Dose Radiotherapy in...